Current and historical daily PE Ratio for OCX (
OncoCyte Corp
) from 2015 to Mar 27 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. OncoCyte stock (OCX) PE ratio as of Mar 27 2023 is 0.
More Details
OncoCyte Corp (OCX) PE Ratio (TTM) Chart
OncoCyte Corp (OCX) PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1259
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| OncoCyte PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2023-03-28 | At Loss | 2023-01-20 | At Loss |
| 2023-03-24 | At Loss | 2023-01-19 | At Loss |
| 2023-03-23 | At Loss | 2023-01-18 | At Loss |
| 2023-03-22 | At Loss | 2023-01-17 | At Loss |
| 2023-03-21 | At Loss | 2023-01-13 | At Loss |
| 2023-03-20 | At Loss | 2023-01-12 | At Loss |
| 2023-03-17 | At Loss | 2023-01-11 | At Loss |
| 2023-03-16 | At Loss | 2023-01-10 | At Loss |
| 2023-03-15 | At Loss | 2023-01-09 | At Loss |
| 2023-03-14 | At Loss | 2023-01-06 | At Loss |
| 2023-03-13 | At Loss | 2023-01-05 | At Loss |
| 2023-03-10 | At Loss | 2023-01-04 | At Loss |
| 2023-03-09 | At Loss | 2023-01-03 | At Loss |
| 2023-03-08 | At Loss | 2022-12-30 | At Loss |
| 2023-03-07 | At Loss | 2022-12-29 | At Loss |
| 2023-03-06 | At Loss | 2022-12-28 | At Loss |
| 2023-03-03 | At Loss | 2022-12-27 | At Loss |
| 2023-03-02 | At Loss | 2022-12-23 | At Loss |
| 2023-03-01 | At Loss | 2022-12-22 | At Loss |
| 2023-02-28 | At Loss | 2022-12-21 | At Loss |
| 2023-02-27 | At Loss | 2022-12-20 | At Loss |
| 2023-02-24 | At Loss | 2022-12-19 | At Loss |
| 2023-02-23 | At Loss | 2022-12-16 | At Loss |
| 2023-02-22 | At Loss | 2022-12-15 | At Loss |
| 2023-02-21 | At Loss | 2022-12-14 | At Loss |
| 2023-02-17 | At Loss | 2022-12-13 | At Loss |
| 2023-02-16 | At Loss | 2022-12-12 | At Loss |
| 2023-02-15 | At Loss | 2022-12-09 | At Loss |
| 2023-02-14 | At Loss | 2022-12-08 | At Loss |
| 2023-02-13 | At Loss | 2022-12-07 | At Loss |
| 2023-02-10 | At Loss | 2022-12-06 | At Loss |
| 2023-02-09 | At Loss | 2022-12-05 | At Loss |
| 2023-02-08 | At Loss | 2022-12-02 | At Loss |
| 2023-02-07 | At Loss | 2022-12-01 | At Loss |
| 2023-02-06 | At Loss | 2022-11-30 | At Loss |
| 2023-02-03 | At Loss | 2022-11-29 | At Loss |
| 2023-02-02 | At Loss | 2022-11-28 | At Loss |
| 2023-02-01 | At Loss | 2022-11-25 | At Loss |
| 2023-01-31 | At Loss | 2022-11-23 | At Loss |
| 2023-01-30 | At Loss | 2022-11-22 | At Loss |
| 2023-01-27 | At Loss | 2022-11-21 | At Loss |
| 2023-01-26 | At Loss | 2022-11-18 | At Loss |
| 2023-01-25 | At Loss | 2022-11-17 | At Loss |
| 2023-01-24 | At Loss | 2022-11-16 | At Loss |
| 2023-01-23 | At Loss | 2022-11-15 | At Loss |
OncoCyte Corp (OCX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
OncoCyte Corp
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
7OC.Germany0KCC.UKOCX.USA IPO Date
2015-12-30Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
